Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Products under Development by Stage of Development | 7 | 1 |
| Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Products under Development by Therapy Area | 8 | 1 |
| Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Products under Development by Indication | 9 | 1 |
| Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Products under Development by Companies | 12 | 2 |
| Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Products under Development by Universities/Institutes | 14 | 2 |
| Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Therapeutics Assessment | 16 | 7 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 2 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 2 |
| Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Companies Involved in Therapeutics Development | 23 | 5 |
| AngioChem Inc. | 23 | 1 |
| ArmaGen Inc. | 24 | 1 |
| Bioasis Technologies Inc. | 25 | 1 |
| RegenxBio Inc. | 26 | 1 |
| Sangamo BioSciences, Inc. | 27 | 1 |
| Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Drug Profiles | 28 | 12 |
| AGT-181 Drug Profile | 28 | 2 |
| Cell Therapy for Mucopolysaccharidosis I Drug Profile | 30 | 1 |
| Cell Therapy to Activate Alpha L-Iduronidase for Hurler Syndrome Drug Profile | 31 | 1 |
| Recombinant Alpha-L-Iduronidase Replacement for Hurler Syndrome Drug Profile | 32 | 1 |
| Recombinant Alpha-L-Iduronidase Replacement for Mucopolysaccharidosis I Drug Profile | 33 | 1 |
| Recombinant Alpha-L-Iduronidase Replacement for Mucopolysaccharidosis I Drug Profile | 34 | 1 |
| RGX-111 Drug Profile | 35 | 2 |
| SB-318 Drug Profile | 37 | 2 |
| X-372 Drug Profile | 39 | 1 |
| Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Dormant Projects | 40 | 1 |
| Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Featured News &Press Releases | 41 | 9 |
| Jul 05, 2016: REGENXBIO Provides Update On Gene Therapy Development Program RGX-111 | 41 | 1 |
| May 09, 2016: Sangamo BioSciences Presents Recent Developments From Research And ZFP Therapeutic Programs In Multiple Presentations At Annual Meeting of the American Society of Gene and Cell Therapy | 41 | 2 |
| Mar 31, 2016: ArmaGen Announces Initiation of Phase 2 Proof-of-Concept Clinical Trial in Brazil to Study AGT-181 for the Treatment of Hurler Syndrome | 43 | 1 |
| Feb 08, 2016: Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I | 44 | 1 |
| Dec 30, 2015: FDA Grants Rare Pediatric Disease Designation to REGENXBIO RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I (MPS I) | 45 | 1 |
| Nov 05, 2015: ArmaGen Receives Rare Pediatric Disease Designation from FDA for AGT-181 for the Potential Treatment of Hurler Syndrome | 45 | 1 |
| Oct 01, 2015: FDA Grants Orphan Drug Designation to REGENXBIO's RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I | 46 | 1 |
| Sep 02, 2015: ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome | 46 | 1 |
| Apr 08, 2015: ArmaGen Announces FDA Acceptance of IND Application for AGT-181 for the Treatment of Hurler Syndrome | 47 | 1 |
| Mar 10, 2015: PacificGMP and ArmaGen Announce Successful Manufacture of ArmaGen's investigational enzyme replacement therapy, AGT-181, for Phase 1 Clinical Trial | 48 | 1 |
| Feb 05, 2014: Mouse Study Shows Gene Therapy May Be Possible Cure for Hurler Syndrome | 48 | 1 |
| Sep 18, 2009: ArmaGen Completes Primate Safety Study For AGT-181 | 49 | 1 |
| Appendix | 50 | 2 |
| Methodology | 50 | 1 |
| Coverage | 50 | 1 |
| Secondary Research | 50 | 1 |
| Primary Research | 50 | 1 |
| Expert Panel Validation | 50 | 1 |
| Contact Us | 50 | 1 |
| Disclaimer | 51 | 1 |
